1. Introduction {#sec1}
===============

Ischemic heart disease (IHD) is a major cause of death and global healthcare burden \[[@B1]\]. Angina pectoris, a symptom of IHD, is a severe chest pain due to ischemia of the heart muscle, during obstruction or spasm of the coronary arteries \[[@B2]\]. In the United States, IHD accounts for 26.6% of all deaths in 2005, with an age-adjusted male-to-female mortality ratio of 1.5 \[[@B3]\]. The morbidity and mortality of angina in middle-aged and elderly people were ranked the top among all common diseases in China \[[@B4]\]. Three categories of conventional Western medicine including nitrates (e.g., isosorbide mononitrate), beta-receptor blockers (e.g., atenolol), and calcium channel blockers (e.g., amlodipine) are commonly used in treating angina \[[@B3]\].

Guanxinning injection (GXN, also known as Danshen Chuanxiong Injection) comprises extracts from two well-known traditional Chinese medicines Danshen (Salvia miltiorrhiza) and Chuanxiong (Ligustrazine, Ligustium Wallichii Franch) \[[@B5]\]. Danshen and its active compounds tanshinones and isotanshinones have bioactivities against myocardial ischemia, inflammation, and angiotensin-converting enzyme \[[@B6]\]. Chuanxiong and its active compounds tetramethylpyrazine and ferulic acid can dilate coronary arteries, increase myocardial oxygen, and decrease platelet aggregation and thrombosis \[[@B7]\].

GXN was tested to be more effective than nitrates \[[@B8]\], beta-receptor blockers \[[@B9]\], and calcium channel blockers \[[@B10]\] in treating angina. Since the launch of GXN (2002) and prior to this study, there has been only one systematic review, which is not compliant with PRISMA \[[@B11]\] and includes only nine randomized controlled trials (RCTs) published in Chinese between 2002 and 2010 \[[@B12]\]. The methods and results of quality assessment of the included RCTs were not clearly reported in the systematic review. Sensitivity and subgroup analyses were missing. Hence, this study aims to provide an internationally accessible, comprehensive, and timely systematic review and meta-analysis in compliance with PRISMA to assess the efficacy of GXN as a monotherapy and combined therapy with conventional Western or Chinese medicines in treating angina pectoris.

2. Methods {#sec2}
==========

The procedures of this systematic review and meta-analysis were conducted in accordance with the PRISMA guideline \[[@B11]\], including the search and selection of studies, data extraction from the studies, and meta-analysis (overall, subgroup, sensitivity, publication bias, and metaregression analysis).

2.1. Search Strategies {#sec2.1}
----------------------

RCTs published on the efficacy of GXN in treating angina pectoris were retrieved from major bibliographical databases including Medline, PubMed, Cochrane Library, ScienceDirect, Embase, China National Knowledge Infrastructure (CNKI), WanFang Data, China Master Theses Full-text Database (CMTD), and China Doctor Dissertations Full-text Database (CDMD) between the inception dates of databases and 2012 (last search on 18 March 2012). A simple search strategy, that is, searching for the keywords "Guanxinning" or "danshen chuanxiong" or "danshenchuanxiong," was used to search all fields. For instance, the search in WanFang Data using the keyword "Guanxinning" found 196 records and "danshen chuanxiong" found 17 records and "danshenchuanxiong" found none. Exact search strategies and query syntax for specific databases were customized according to the same strategy.

2.2. Study Selection {#sec2.2}
--------------------

Inclusion criteria for each study were (a) the participants were suffering from and being treated for angina pectoris; (b) the study was claimed as an RCT; (c) the study compared the efficacy of GXN with conventional (Western and Chinese medicine) drugs. Exclusion criteria were (a) the study was a duplicated or redundant publication and (b) the study did not include symptomatic improvement as a major outcome.

Two reviewers (Y. Jia and F. Pan) independently searched the databases and selected studies according to the inclusion and exclusion criteria. Disagreements between reviewers were resolved by consensus after discussion. [Figure 1](#fig1){ref-type="fig"} shows a flow diagram of study selection.

2.3. Data Extraction {#sec2.3}
--------------------

Two reviewers (Y. Jia and F. Pan) independently extracted data items, including (a) years of publication; (b) numbers of authors; (c) follow-up periods; (d) baseline characteristics of participants between groups; (e) sample sizes; (f) outcome measures; (g) dosages and follow-up periods; (h) type of angina; (i) frequencies of adverse events (AE); and (j) the type of angina.

2.4. Quality Assessment of Included Studies {#sec2.4}
-------------------------------------------

Two reviewers (Y. Jia and F. Pan) independently assessed the quality of the included studies according to the Jadad scale \[[@B13]\], its refined version the *M* scale \[[@B14]\], and the Cochrane Collaboration\'s tool for assessing risk of bias \[[@B15]\]. The Jadad scale focused on three criteria including "randomization," "blinding," and "dropouts" for assessing the quality of RCT. The *M* scale added two criteria "baseline comparison of participants" and "adverse event report" on top of the Jadad scale. The Cochrane Collaboration\'s tool for assessing risk of bias includes "random sequence generation," "allocation concealment," "blinding of participants and personnel," "blinding of outcome assessment (patient-reported outcomes)," "blinding of outcome assessment (SYMPTOMS)," "incomplete outcome data addressed," "reporting bias," and "other sources of bias."

2.5. Criteria for Symptomatic and ECG Improvements {#sec2.5}
--------------------------------------------------

Effective symptomatic improvements should achieve at least 50% (basic) or 80% (significant) reduction in frequency of feeling angina chest pain \[[@B16]\]. Effective ECG improvements should achieve (a) at least 0.05 mV lowering at ST segment in ECG (basic) or (b) nearly normal (significant) ECG during an exercise test according to the International Society and Federation of Cardiology/World Health Organization \[[@B16]\].

2.6. Meta-Analysis {#sec2.6}
------------------

Effect sizes were represented by odds ratios (ORs) \[[@B17]\] and their 95% confidence intervals (CI) \[[@B18]\]. Overall meta-analysis and subgroup analysis employed the random-effects model for conservative generalizability. Heterogeneity among studies was assessed by Chi-squared (*χ* ^2^) and I-squared (*I* ^2^) tests \[[@B19]\].

2.7. Subgroup and Sensitivity Analyses {#sec2.7}
--------------------------------------

Subgroup analysis was conducted to evaluate the overall effects in the subgroups according to years of publication (≤2008 or \>2008), numbers of authors (1 or \>1), follow-up periods (≤14 days or \>14 days), sample sizes (\<mean sample size or ≥mean sample size), quality scores of the studies (\<mean or ≥mean), different type of angina, and different daily dosage of GXN. The overall effects were also analyzed in subgroups of GXN for monotherapy and adjunctive therapy. Sensitivity analysis was carried out according to different criteria outcomes (basic or significant) in SYMPTOMS and ECG and excluding studies with maximum GXN dosage to assess their influence on the overall effect sizes. The Mann-Whitney-Wilcoxon test was used to compare two subgroups. The Kruskal-Wallis test and the Bonferroni correction were used to compare multiple subgroups. Kendall correlation between ORs of symptoms and ECG was performed.

2.8. Metaregression and Risk of Bias across Studies {#sec2.8}
---------------------------------------------------

Funnel plots \[[@B20]\], Begg\'s test \[[@B21]\], and Egger\'s test \[[@B22]\] were employed to assess publication bias. Trim-and-fill method \[[@B23]\] was conducted to identify and correct the funnel plot asymmetry arising from publication bias. Metaregression \[[@B24]\] was conducted to find the possible relationship between the overall effects and the factors such as sample sizes, follow-up periods, *M* scores, and years of publication.

2.9. Adverse Events {#sec2.9}
-------------------

Information about adverse events (AEs) of RCTs, including nonreported adverse events and types and frequency of adverse events reported, was tabulated and analyzed by basic statistics.

2.10. Statistical Analysis {#sec2.10}
--------------------------

All data analyses, including meta-analysis, forest plot generation, funnel plot generation, metaregression, Kendall correlation, Mann-Whitney-Wilcoxon test, Kruskal-Wallis test, Begg\'s test, and Egger\'s test, were performed using statistical software R \[[@B25]\] and its "metafor" package for meta-analysis. *P* values lower than 0.05 were considered statistically significant.

3. Results {#sec3}
==========

3.1. Study Selection {#sec3.1}
--------------------

[Figure 1](#fig1){ref-type="fig"} depicts the process of study selection. The search of bibliographical databases found 401 records, including 196 records from WanFang Data, 162 records from CNKI, 19 records from CMTD, 11 records from ScienceDirect, 6 records from Medline, 5 records from PubMed, and 2 records from CDMD. According to prespecified selection criteria as described in Methods, 65 studies \[[@B26]--[@B90]\] were included for further quality assessment and meta-analysis.

3.2. Study Characteristics {#sec3.2}
--------------------------

[Table 1](#tab1){ref-type="table"} lists the main characteristics of the included studies. All included studies were published in the Chinese language between 2004 and 2011 with a total of 6064 participants. The mean sample size was 93.3 (median: 88.0; 95% CI: \[56.5, 130.1\]). The follow-up periods were between 1 and 30 days. GXN was compared with the conventional treatments in the included RCTs. Drugs in control group mainly included nitrates, beta-receptor blockers, calcium channel blockers, angiotensin-converting enzyme inhibitors, and some conventional Chinese medicinal products for treating heart disease. Fifty-nine out of 65 RCTs employed GXN plus the conventional treatments in the treatment group while the conventional treatments were employed in control group. Dosage details were listed in Supplementary Table  1 in the Supplementary Material available online at <http://dx.doi.org/10.1155/2013/282707>. For outcome measures, all 65 included studies reported symptomatic (SYMPTOMS) changes while 38 studies also reported ECG changes.

3.3. Quality Assessment of Included Studies {#sec3.3}
-------------------------------------------

[Table 2](#tab2){ref-type="table"} shows the results of quality assessment according to the Jadad scales, *M* scales, and the Cochrane Collaboration\'s tool. According to the Jadad scale (with a possible range between 0 and 5 points), 63 studies of all included studies scored 2 with two items "randomization" and "dropouts," one study \[[@B34]\] scored 3, and one study \[[@B47]\] scored 4. According to the *M* scale, six studies scored 2, three studies scored 2.5, 30 studies scored 3, 24 studies scored 4, and 2 studies scored 5. Fifty included studies reported baseline comparison of participants in experiment and control groups. Thirty-one studies did not report adverse events. Three studies reported types of adverse events. Thirty-one studies reported types and numbers of adverse events. The assessment results of the Cochrane Collaboration\'s tool showed (1) low risk of bias in random sequence generation for selection bias, blinding of outcome assessment (SYMPTOMS) for detection bias, and incomplete outcome data addressed for attrition bias, (2) high risk of bias in allocation concealment for selection bias, blinding of participants and personnel for performance bias, blinding of outcome assessment (patient-reported outcomes) for detection bias, and reporting bias for selecting reporting, and (3) unclear risk of bias in other sources of bias for other bias.

3.4. Overall Effects of Included Studies {#sec3.4}
----------------------------------------

As shown in [Figure 2](#fig2){ref-type="fig"} and [Table 3](#tab3){ref-type="table"}, the overall OR of SYMPTOMS was 3.32 (95% CI: \[2.72, 4.04\], *Z* = 11.93, *P* \< 0.0001) with significant heterogeneity (tau = 0.23, *I* ^2^ = 37%, *P* = 0.0030) among the 65 studies with SYMPTOMS outcome. [Figure 3](#fig3){ref-type="fig"} and [Table 4](#tab4){ref-type="table"} show that the overall OR of ECG was 2.59 (95% CI: \[2.14, 3.15\], *Z* = 9.68, *P* \< 0.0001) with nonsignificant heterogeneity (tau = 0.11, *I* ^2^ = 32%, *P* = 0.0539) among the 38 studies with ECG outcome. Both ORs (SYMPTOMS and ECG) indicated that GXN was more effective than the drugs in control group in treating angina pectoris. The Kendall correlation between SYMPTOMS and ECG in ORs was statistically significant (tau = 0.2644; *P* = 0.0200).

3.5. Subgroup Analysis {#sec3.5}
----------------------

ORs of the subgroups in both SYMPTOMS ([Table 3](#tab3){ref-type="table"}) and ECG ([Table 4](#tab4){ref-type="table"}) were compared based on the study characteristics including *M* scores (≤3 or \>3), sample sizes (\<93 or ≥93), number of authors (1 or \>1), years of publication (before or after January 1, 2008), reports of trial dates (yes or no), baseline comparison of participants (yes or no), reports of adverse events (yes or no), follow-up periods (≤14 days or \>14 days), GXN daily dosages (\<20 mL, 20 mL, \>20 mL), different angina types, and different treatments including GXN monotherapy versus control treatment, GXN + control versus control, and GXN mixed treatment + control versus control. There was no statistically significant difference between ORs of these subgroups.

3.6. Sensitivity Analysis {#sec3.6}
-------------------------

When the improvement criteria were raised to the significant level from the basic level, the overall results remained effective (i.e., OR \> 1) and statistically significant. The OR of overall SYMPTOMS decreased from 3.32 to 1.75 (95% CI: \[1.54, 1.98\], *Z* = 8.65, *P* \< 0.0001). The OR of overall ECG decreased from 2.59 to 1.84 (95% CI: \[1.59, 2.14\], *Z* = 8.06, *P* \< 0.0001). There was a statistically significant correlation between the changes in ORs of SYMPTOMS and ECG outcomes (tau = 0.2971, *P* = 0.0089). When study \[[@B33]\] with maximum GXN dosage was excluded, there was no statistically significant difference between ORs of groups in both SYMPTOMS and ECG data.

3.7. Metaregression {#sec3.7}
-------------------

[Table 5](#tab5){ref-type="table"} shows the results of metaregression between log OR and study characteristics. There seemed to be no statistically significant relationship between GXN\'s efficacy and study characteristics, except that follow-up periods made a significant difference (*P* = 0.0093) on the log OR with ECG data.

3.8. Risk of Bias Across Studies {#sec3.8}
--------------------------------

Visual assessment of funnel plots ([Figure 4](#fig4){ref-type="fig"}) found obvious asymmetry, indicating that there were publication biases in the results of both SYMPTOMS and ECG. Egger\'s test (SYMPTOMS: *t* = 2.0555, *P* = 0.0440; ECG: *t* = 0.9358, *P* = 0.3556) and Begg\'s test (SYMPTOMS: *z* = 0.1898, *P* = 0.0257; ECG: *z* = 0.2571, *P* = 0.0236) detected statistically significant publication biases. Trim-and-fill method found that there were 24 missing studies for SYMPTOMS and 13 missing studies for ECG on the left side of the corresponding funnel plots.

3.9. Adverse Events {#sec3.9}
-------------------

As shown in [Table 6](#tab6){ref-type="table"}, the most frequently reported adverse event of GXN was headache. All adverse effects were minor or well tolerated as they did not cause dropouts except in one study \[[@B31]\] where six participants dropped out because of the adverse effects. Headache, epigastria discomfort, and palpitation were noted as the top three adverse effects of drugs in control group. Adverse effects of GXN were less than those of control drugs in the number of types, severity, and frequency.

4. Discussion {#sec4}
=============

This study provides the first comprehensive, up-to-date, and PRISMA-compliant systematic review on the efficacy of GXN in treating angina pectoris. Among 65 included RCTs with 6064 participants, overall ORs of SYMPTOMS and ECG were 3.32 (95% CI: \[2.72, 4.04\]) (*P* \< 0.0001) and 2.59 (95% CI: \[2.14, 3.15\]) (*P* \< 0.0001), respectively. Subgroup analysis also found statistical significance in the differences between GXN treatment group and control group in testing GXN monotherapy and adjunctive therapy. These results indicated that GXN treatment is effective in treating angina pectoris.

The results of this meta-analysis were robust as shown in subgroup analysis, sensitivity analysis, and metaregression on various parameters including sample sizes, follow-up periods, daily dosages of GXN, types of angina pectoris, and the quality scores of RCTs. Although funnel plots, Begg\'s test, Egger\'s test, and trim-and-fill method found publication biases, the overall effects would still favor GXN treatment after enough number of less favorable studies were published to restore the symmetry of funnel plots.

The efficacy of GXN in both monotherapy and adjunctive therapy of angina pectoris exemplifies potential uses of chemical components of GXN as one of the herbal products that have offered great potentials in developing multitarget agents to treat complex diseases \[[@B91]\]. Experimental studies also showed that the aqueous extracts from both Danshen and Chuanxiong significantly reduced the myocardial infarct size in rat myocardial ischemia/reperfusion injury \[[@B92]\]. As seen from the clinical and experimental findings, GXN seems to be a promising resource for identifying new therapeutic agents or new drug targets \[[@B93]\] in treating angina pectoris. Although subgroup analysis and sensitivity analysis did not suggest any significant factors which would influence the efficacy of GXN, clinical heterogeneity may contribute to heterogeneity of this meta-analysis.

The limitations of this study include small sample sizes and short follow-up periods. The mean sample size was 93, which was lower than 124 as required by an alpha of 0.05, the proportions of 0.899 for GXN and 0.742 for control group, and a power of 0.8 \[[@B94]\]. The patients of angina pectoris would need long-term treatment \[[@B95]\], but most available RCTs have short follow-up periods.

Another major limitation of this systematic review is the low quality of included studies although most of included RCT reports achieved the average quality of Chinese RCTs \[[@B96], [@B97]\], which is still inadequate. Almost all (63 out of 65) studies scored 2 at the Jadad scale, which ranges between 0 and 5. One study \[[@B34]\] reported single blinding and another study \[[@B47]\] reported double blinding. Twenty-four RCTs scored 4 at the *M* scale and 40 RCTs scored less than 4 at the *M* scale. There is evidence of the Cochrane Library\'s tool to show high risks of bias with the aspects of selection bias, performance bias, and detection bias. More than that, less than but almost half of included RCTs (28/65) did not report adverse events, one possible reason of which is high reporting bias for selecting reporting. Safety of GXN intervention cannot be assessed because of incomplete reporting data. Despite the fact that subgroup analysis found no statistically significant differences in ORs of SYMPTOMS and ECG between the RCTs of low and medium *M* scores, high-quality RCTs would be necessary to further support the efficacy of GXN-based medicines over conventional Western drugs in treating angina pectoris.

Seventy-three out of 6064 participants had AE. The main AEs included headache (19), skin ecchymosis (14), epigastria discomfort (12), and palpitation (11). Headache was the most frequent AE in this paper. The AE mechanisms of GXN are not clear and definite. The functions of dilated blood vessels and coronary artery blood circulation activating are possible reasons that lead to adverse events.

According to this meta-analysis, GXN seems to be effective in treating angina pectoris. As GXN contains the herbal extracts from Salvia miltiorrhiza and Ligustrazine, hence DSS, PAC, PAL, CAA, and SAB as the main active ingredients with potential effects on coronary heart disease, angina pectoris, and cardiovascular diseases \[[@B98]\] by enhancing coronary blood flow, improving the myocardial systolic functions, and protecting myocardial cells \[[@B99]\], further clinical, herbal formulation and pharmacological studies are warranted for further research and development.

5. Conclusion {#sec5}
=============

This meta-analysis of eligible RCTs provides evidence that GXN is effective in treating angina pectoris. This evidence warrants further RCTs of higher quality, longer follow-up periods, larger sample sizes, and multicentres/multicountries for more extensive subgroup, sensitivity, and metaregression analyses.

Supplementary Material {#supplementary-material-sec}
======================

###### 

Supplementary Table 1 provides the treatment (drugs and dosages for control and treatment groups) details about the RCTs included in this study.

###### 

Click here for additional data file.
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###### 

Characteristics of the included studies.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                 Number of authors   Trial date report   Sample\   Followup\   Baseline comparison   AE    Outcomes\   Treatment group dosage                                      Angina
                                                                size      (day)                                   measure                                                                 
  --------------------- ------------------- ------------------- --------- ----------- --------------------- ----- ----------- ----------------------------------------------------------- ----------
  Chen 2009             1                   1                   100       15          1                     0     SYM, ECG    GXN 20 mL/d + CG                                            Angina

  Chen et al. 2011      3                   1                   100       10          0                     0     SYM         GXN 20 mL/d + CG                                            Angina

  Chen 2006             1                   1                   62        14          1                     1     SYM, ECG    GXN 20 mL/d + CG                                            Angina

  Cheng and Zang 2010   2                   1                   43        14          1                     0     SYM         GXN 30 mL/d + CG                                            Unstable

  Cheng et al. 2011     3                   1                   76        14          1                     1     SYM, ECG    GXN 30 mL/d + CG                                            Angina

  Dong XP 2009          1                   0                   100       1           0                     0.5   SYM         GXN 20 mL/d                                                 Angina

  Fu and Meng 2011      2                   0                   47        10          1                     0     SYM, ECG    GXN 20 mL/d + CG                                            Angina

  Fu et al. 2010        4                   1                   56        14          1                     0     SYM, ECG    GXN 200 ml + CG + shenmaiyin 40 ml                          Angina

  Gao et al. 2005       3                   1                   60        14          1                     1     SYM, ECG    GXN 20 mL/d                                                 Angina

  Gong et al. 2009      3                   1                   85        14          1                     1     SYM, ECG    GXN 20 mL/d + xueshuantong 20 ml                            Stable

  He and Meng 2007      1                   1                   49        15          1                     0     SYM         GXN 20 mL/d + CG                                            Unstable

  He 2009               1                   1                   120       28          1                     1     SYM, ECG    GXN 30 mL/d + atorvastatin 10 mg                            Unstable

  Hou and Gao 2009      2                   1                   128       14          1                     1     SYM, ECG    GXN 20 mL/d + CG                                            Stable

  Huang et al. 2011     4                   0                   120       7           1                     1     SYM         GXN 20 mL/d + CG + xueshuantong 400 mg                      Angina

  Jiang et al. 2010     3                   1                   116       10          1                     0     SYM, ECG    GXN 20 mL/d + CG                                            Unstable

  Jiang 2009            1                   1                   68        20          1                     1     SYM, ECG    GXN 20 mL/d                                                 Angina

  Jiang et al. 2010     5                   0                   56        7           0                     1     SYM         GXN 30 mL/d                                                 Angina

  Kong 2009             1                   0                   100       14          1                     1     SYM         GXN 30 mL/d + CG                                            Unstable

  Lan et al. 2006       3                   1                   64        14          1                     1     SYM         GXN 20 mL/d                                                 Angina

  Li and Jia 2011       2                   1                   200       14          1                     0     SYM, ECG    GXN 30 mL/d + CG                                            Angina

  Li and Lei 2005       2                   1                   156       14          0                     1     SYM, ECG    GXN 20 mL/d + CG                                            Angina

  Li et al. 2009        5                   1                   168       14          1                     0     SYM         GXN 20 mL/d + CG                                            Angina

  Li and Ran 2009       2                   1                   160       10          1                     1     SYM         GXN 20 mL/d + CG                                            Angina

  Li 2004               1                   0                   83        7           1                     0     SYM, ECG    GXN 20 mL/d + CG                                            Unstable

  Liang and Feng 2010   2                   0                   120       14          1                     0     SYM, ECG    GXN 20 mL/d + CG                                            Unstable

  Liu 2004              1                   1                   104       10          1                     1     SYM         GXN 20 mL/d + CG                                            Unstable

  Liu and Li 2007       2                   1                   88        12          0                     1     SYM         GXN 20 mL/d + CG                                            Unstable

  Liu 2005              1                   1                   80        30          1                     0     SYM, ECG    GXN 20 mL/d + CG                                            Unstable

  Liu 2011              1                   1                   152       28          1                     0     SYM, ECG    GXN 20 mL/d + CG                                            Angina

  Lu et al. 2006        3                   1                   68        30          1                     0     SYM         GXN 30 mL/d + CG                                            Angina

  Ma and Peng 2008      2                   1                   120       14          1                     0     SYM         GXN 30 mL/d + CG                                            Unstable

  Nie and Chen 2007     2                   1                   60        14          1                     0     SYM, ECG    GXN 20 mL/d + CG                                            Angina

  Qiao and Wu 2004      2                   0                   81        28          1                     1     SYM, ECG    GXN 20 mL/d + CG                                            Stable

  Song 2010             1                   1                   82        7           0                     0.5   SYM         GXN 20 mL/d + CG + diltiazem 90 mg/d                        Unstable

  Su 2009               1                   1                   90        15          0                     1     SYM, ECG    GXN 6 mL/d + CG                                             Angina

  Sun 2010              1                   1                   90        14          1                     0     SYM, ECG    GXN 30 mL/d + CG                                            Unstable

  Sun et al. 2006       5                   1                   98        15          0                     0     SYM         GXN 20 mL/d + CG                                            Angina

  Tian and Wu 2006      2                   1                   62        14          1                     1     SYM         GXN 30 mL/d + CG                                            Unstable

  Wan and Xu 2009       2                   0                   120       14          1                     1     SYM, ECG    GXN 30 mL/d + CG                                            Unstable

  Wang 2007             1                   1                   100       14          1                     1     SYM, ECG    GXN 30 mL/d + CG                                            Angina

  Wang 2011             1                   1                   85        14          1                     1     SYM, ECG    GXN 20 mL/d + CG                                            Unstable

  Wang 2011             2                   1                   112       14          1                     1     SYM, ECG    GXN 20 mL/d + CG                                            Unstable

  Wang and Ji 2008      2                   1                   60        14          0                     0     SYM, ECG    GXN 20 mL/d + CG                                            Unstable

  Wang and Sun 2007     2                   1                   92        10          0                     0     SYM         GXN 20 mL/d + CG                                            Unstable

  Wang 2005             2                   1                   60        15          1                     0     SYM         GXN 20 mL/d + CG                                            Unstable

  Wang 2010             1                   0                   80        14          1                     1     SYM, ECG    GXN 20 mL/d + CG                                            Stable

  Wang 2005             1                   0                   76        15          0                     0     SYM         GXN 20 mL/d + CG + shenmai 30 mL/d + tongxinluo 9 pills/d   Unstable

  Wang 2005             1                   1                   60        14          1                     1     SYM         GXN 20 mL/d + CG                                            Unstable

  Wang et al. 2011      4                   1                   60        14          1                     1     SYM         GXN 20 mL/d + CG                                            Unstable

  Wu et al. 2008        3                   0                   108       14          1                     0     SYM         GXN 20 mL/d + CG                                            Angina

  Wu et al. 2011        4                   1                   144       7           1                     0     SYM         GXN 20 mL/d + CG + shenmai 50 mL/d                          Unstable

  Xia 2011              1                   1                   90        14          1                     0     SYM, ECG    GXN 30 mL/d + CG                                            Unstable

  Yang and Ma 2008      2                   1                   90        14          1                     0     SYM, ECG    GXN 30 mL/d + CG                                            Unstable

  Ye et al. 2008        3                   0                   76        15          0                     1     SYM         GXN 20 mL/d + CG                                            Unstable

  Yu and Wang 2009      2                   1                   75        15          1                     0     SYM, ECG    GXN 20 mL/d + CG                                            Angina

  Yuan 2005             1                   0                   104       14          1                     0     SYM, ECG    GXN 20 mL/d + CG                                            Angina

  Zhang 2005            1                   1                   60        14          1                     0     SYM, ECG    GXN 10 mL/d                                                 Angina

  Zhang 2010            1                   1                   240       15          1                     1     SYM, ECG    GXN 20 mL/d + CG                                            Unstable

  Zhang 2004            1                   1                   102       14          1                     1     SYM, ECG    GXN 10 mL/d + CG + ginkgo leaf injection 10 mL/d            Angina

  Zhang 2004            1                   1                   42        7           0                     1     SYM         GXN 20 mL/d + CG                                            Angina

  Zhao et al. 2010      6                   1                   100       14          1                     1     SYM, ECG    GXN 10 mL/d + CG + xueshuangtong 120 mg                     Unstable

  Zhao and An 2008      2                   1                   90        28          1                     1     SYM, ECG    GXN 20 mL/d + CG + simvastatin 10--20 mg/d                  Unstable

  Zhao 2010             1                   1                   86        14          1                     0     SYM, ECG    GXN 30 mL/d + CG                                            Angina

  Zhong et al. 2007     8                   1                   60        10          0                     0     SYM         GXN 20 mL/d + CG                                            Angina

  Zhu 2005              1                   1                   80        15          0                     0.5   SYM, ECG    GXN 20 mL/d + CG                                            Unstable
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

GXN is Guanxinning injection; LMWH is low molecular weight heparin; and shenmai is Shenmai injection. CG is interventions of control group; SYM is SYMPTOMS; ECG is electrocardiogram; and AE is adverse event. The column of "Trial date report" shows that study did (1) or did not (0) report the trial date. The column of "Baseline comparison" shows that the study did (1) or did not (0) report the baseline comparison between the treatment and control groups.

###### 

Quality assessment of included studies.

  Study                 C1    C2        C3        C4     C5    C6    C7        C8        Comparable   Random   Blind   Dropout   AE    Jadad   *M*
  --------------------- ----- --------- --------- ------ ----- ----- --------- --------- ------------ -------- ------- --------- ----- ------- -----
  Chen 2009             Low   High      High      High   Low   Low   High      High      1            1        0       1         0     2       3
  Chen et al. 2011      Low   Unclear   High      High   Low   Low   High      High      0            1        0       1         0     2       2
  Chen 2006             Low   High      High      High   Low   Low   Low       Low       1            1        0       1         1     2       4
  Cheng and Zeng 2010   Low   High      High      High   Low   Low   High      High      1            1        0       1         0     2       3
  Cheng et al. 2011     Low   High      High      High   Low   Low   Low       Low       1            1        0       1         1     2       4
  Dong 2009             Low   High      High      High   Low   Low   Unclear   High      0            1        0       1         0.5   2       2.5
  Fu and Meng 2011      Low   High      High      High   Low   Low   High      High      1            1        0       1         0     2       3
  Fu et al. 2010        Low   High      High      High   Low   Low   High      High      1            1        0       1         0     2       3
  Gao et al. 2005       Low   Low       High      High   Low   Low   Low       Low       1            1        1       1         1     3       5
  Gong et al. 2009      Low   High      High      High   Low   Low   Low       Low       1            1        0       1         1     2       4
  He 2007               Low   High      High      High   Low   Low   High      High      1            1        0       1         0     2       3
  He 2009               Low   High      High      High   Low   Low   Low       Low       1            1        0       1         1     2       4
  Hou and Gao 2009      Low   High      High      High   Low   Low   Low       Low       1            1        0       1         1     2       4
  Huang et al. 2011     Low   High      High      High   Low   Low   Low       Low       1            1        0       1         1     2       4
  Jiang et al. 2010     Low   High      High      High   Low   Low   High      High      1            1        0       1         0     2       3
  Jiang 2009            Low   High      High      High   Low   Low   Low       Low       1            1        0       1         1     2       4
  Jiang et al. 2010     Low   High      High      High   Low   Low   Low       Low       0            1        0       1         1     2       3
  Kong 2009             Low   High      High      High   Low   Low   Unclear   Low       1            1        0       1         1     2       4
  Lan et al. 2006       Low   High      High      High   Low   Low   Low       Low       1            1        0       1         1     2       4
  Li and Jia 2011       Low   High      High      High   Low   Low   High      High      1            1        0       1         0     2       3
  Li and Lei 2005       Low   High      High      High   Low   Low   Low       Low       0            1        0       1         1     2       3
  Li et al. 2009        Low   Low       Low       Low    Low   Low   High      High      1            1        2       1         0     4       5
  Li and Ran 2009       Low   High      High      High   Low   Low   Low       Low       1            1        0       1         1     2       4
  Li 2004               Low   High      High      High   Low   Low   High      Low       1            1        0       1         0     2       3
  Liang and Feng 2010   Low   High      High      High   Low   Low   High      High      1            1        0       1         0     2       3
  Liu 2004              Low   High      High      High   Low   Low   Low       Low       1            1        0       1         1     2       4
  Liu and Li 2007       Low   High      High      High   Low   Low   High      High      0            1        0       1         1     2       3
  Liu 2005              Low   High      High      High   Low   Low   High      High      1            1        0       1         0     2       3
  Liu 2011              Low   High      High      High   Low   Low   High      High      1            1        0       1         0     2       3
  Lu et al. 2006        Low   High      High      High   Low   Low   High      High      1            1        0       1         0     2       3
  Ma and Peng 2008      Low   High      High      High   Low   Low   Low       Low       1            1        0       1         0     2       3
  Nie and Chen 2007     Low   High      High      High   Low   Low   High      High      1            1        0       1         0     2       3
  Qiao and Wu 2004      Low   High      High      High   Low   Low   Low       Low       1            1        0       1         1     2       4
  Song 2010             Low   High      High      High   Low   Low   Low       Unclear   0            1        0       1         0.5   2       2.5
  Su 2009               Low   Unclear   High      High   Low   Low   Low       Low       0            1        0       1         1     2       3
  Sun 2010              Low   High      High      High   Low   Low   High      High      1            1        0       1         0     2       3
  Sun et al. 2006       Low   High      High      High   Low   Low   High      Unclear   0            1        0       1         0     2       2
  Tian and Wu 2006      Low   High      High      High   Low   Low   Low       Low       1            1        0       1         1     2       4
  Wan and Xu 2009       Low   High      High      High   Low   Low   Low       Low       1            1        0       1         1     2       4
  Wang 2007             Low   High      High      High   Low   Low   Low       High      1            1        0       1         1     2       4
  Wang 2011             Low   High      High      High   Low   Low   Low       Low       1            1        0       1         1     2       4
  Wang 2011             Low   High      High      High   Low   Low   Low       Low       1            1        0       1         1     2       4
  Wang and Ji 2008      Low   High      High      High   Low   Low   High      High      0            1        0       1         0     2       2
  Wang and Sun 2007     Low   High      High      High   Low   Low   High      Unclear   0            1        0       1         0     2       2
  Wang 2005             Low   High      High      High   Low   Low   High      High      1            1        0       1         0     2       3
  Wang 2010             Low   High      High      High   Low   Low   Low       Low       1            1        0       1         1     2       4
  Wang 2005             Low   High      High      High   Low   Low   High      Unclear   0            1        0       1         0     2       2
  Wang 2005             Low   Low       Unclear   High   Low   Low   Low       Low       1            1        0       1         1     2       4
  Wang et al. 2011      Low   High      High      High   Low   Low   Low       Low       1            1        0       1         1     2       4
  Wu et al. 2008        Low   High      High      High   Low   Low   High      Unclear   1            1        0       1         0     2       3
  Wu et al. 2011        Low   High      High      High   Low   Low   High      High      1            1        0       1         0     2       3
  Xia 2011              Low   Low       Unclear   High   Low   Low   High      Unclear   1            1        0       1         0     2       3
  Yang and Ma 2008      Low   Low       Unclear   High   Low   Low   High      High      1            1        0       1         0     2       3
  Ye et al. 2008        Low   High      High      High   Low   Low   Low       Low       0            1        0       1         1     2       3
  Yu and Wang 2009      Low   High      High      High   Low   Low   High      High      1            1        0       1         0     2       3
  Yuan 2005             Low   High      High      High   Low   Low   High      High      1            1        0       1         0     2       3
  Zhang 2005            Low   High      High      High   Low   Low   High      High      1            1        0       1         0     2       3
  Zhang 2010            Low   High      High      High   Low   Low   Low       Low       1            1        0       1         1     2       4
  Zhang 2004            Low   High      High      High   Low   Low   Low       Low       1            1        0       1         1     2       4
  Zhang 2004            Low   High      High      High   Low   Low   Low       High      0            1        0       1         1     2       3
  Zhao et al. 2010      Low   High      High      High   Low   Low   Low       Low       1            1        0       1         1     2       4
  Zhao and An 2008      Low   High      High      High   Low   Low   Low       Low       1            1        0       1         1     2       4
  Zhao 2010             Low   High      High      High   Low   Low   High      Unclear   1            1        0       1         0     2       3
  Zhong et al. 2007     Low   High      High      High   Low   Low   High      High      0            1        0       1         0     2       2
  Zhu 2005              Low   High      High      High   Low   Low   Unclear   Unclear   0            1        0       1         0.5   2       2.5

C1 is random sequence generation for selection bias; C2 is allocation concealment for selection bias; C3 is blinding of participants and personnel for performance bias; C4 is blinding of outcome assessment (patient-reported outcomes) for detection bias; C5 is blinding of outcome assessment (SYMPTOMS) for detection bias; C6 is incomplete outcome data addressed for attrition bias; C7 is reporting bias for selecting reporting; C8 is other sources of bias for other bias; Comparable is participants in treat group and control group comparable; Random is study described as randomized; Blind is study described as blinding; Dropout is withdrawals and dropouts of participants; AE is the adverse effects; Low is low risk of bias; High is high risk of bias; Unclear is unclear risk of bias.

###### 

Subgroups and sensitivity analysis on SYMPTOMS outcomes.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------
                          Group       Number of\   Number of\     OR              Wilcoxon\          95% CI       Z          *P* (eff)   *I* ^2^   *χ* ^2^    *P* (het)
                                      RCTs         participants                   test                                                                        
  ----------------------- ----------- ------------ -------------- --------------- ------------------ ------------ ---------- ----------- --------- ---------- -----------
  *M* score               ≤3          40           3625           3.21            *W* = 546          2.36, 4.35   7.46       \<0.0001    54%       0.50       \<0.0001

  \>3                     25          2439         3.51           *P* = 0.5395    2.78, 4.43         10.50        \<0.0001   0%          0         0.9858     

  Sample size             \<93        39           2772           3.22            *W* = 445.5        2.59, 4.01   10.51      \<0.0001    0%        0          0.6150

  ≥93                     26          3292         3.37           *P* = 0.4140    2.39, 4.76         6.89         \<0.0001   60%         0.47      \<0.0001   

  Number of authors       1           27           2485           3.18            *W* = 1189         2.39, 4.24   7.92       \<0.0001    28%       0.16       0.1253

  \>1                     38          3579         3.40           *P* = 0.7558    2.60, 4.46         8.87         \<0.0001   44%         0.30      0.0031     

  Publication year        ≤2008       31           2495           3.80            *W* = 441.5        3.01, 4.81   11.19      \<0.0001    1%        0.01       0.2929

  \>2008                  34          3569         2.94           *P* = 0.2642    2.20, 3.93         7.32         \<0.0001   48%         0.34      0.0016     

  Trial date report       Reported    51           4793           3.19            *W* = 2112.5       2.57, 3.95   10.52      \<0.0001    36%       0.21       0.0189

  Not reported            14          1271         3.84           *P* = 1         2.33, 6.33         5.28         \<0.0001   47%         0.40      0.0254     

  Baseline\               Reported    50           4808           3.56            *W* = 2112.5       2.84, 4.45   11.10      \<0.0001    40%       0.25       0.0057
  comparison                                                                                                                                                  

  Not reported            15          1256         2.53           *P* = 1         1.75, 3.68         4.89         \<0.0001   14%         0.08      0.1545     

  Adverse\                Reported    31           2947           3.20            *W* = 1006         2.58, 3.97   10.59      \<0.0001    0%        0          0.4304
  events                                                                                                                                                      

  Not reported            34          3117         3.48           *P* = 0.4678    2.53, 4.78         7.68         \<0.0001   51%         0.44      0.0003     

  Follow-up\              ≤14         48           4461           3.38            *W* = 440          2.75, 4.16   11.51      \<0.0001    28%       0.14       0.1321
  period (day)                                                                                                                                                

  \>14                    17          1603         3.05           *P* = 0.6382    1.81, 5.16         4.18         \<0.0001   61%         0.71      0.0005     

  GXN daily               6--200 mL   65           6064           3.32            *W* = 2059         2.72, 4.04   11.93      \<0.0001    37%       0.23       0.0030

  Dosage (mL)             6--30 mL    64           6008           3.34            *P* = 0.9231       2.73, 4.07   11.83      \<0.0001    38%       0.24       0.0025

  GXN daily               \<20        4            352            3.42            *χ* ^2^ = 0.4290   1.48, 7.91   2.88       0.0040      38%       0.28       0.1717

  Dosage (mL)             20          45           4235           3.16            df = 2             2.45, 4.07   8.85       \<0.0001    46%       0.33       0.0004

  \>20                    16          1477         3.87           *P* = 0.8069    2.84, 5.29         8.51         \<0.0001   0%          0         0.8315     

  Types of angina         Stable      4            374            3.42            *χ* ^2^ = 0.9900   1.89, 6.21   4.05       \<0.0001    0%        0          0.7151

  Unstable                31          2892         3.07           df = 2          2.26, 4.16         7.18         \<0.0001   47%         0.34      0.0013     

  Angina                  30          2798         3.61           *P* = 0.6096    2.72, 4.81         8.81         \<0.0001   32%         0.19      0.1179     

  Improvement             \>50%       65           6064           3.32            *W* = 02.5         2.72, 4.04   11.93      \<0.0001    37%       0.23       0.0030

  \>80%                   63          5856         1.75           *P* \< 0.0001   1.54, 1.98         8.65         \<0.0001   25%         0.06      0.0557     

  GXN                     1           6            408            3.19            *χ* ^2^ = 0.4891   1.86, 5.49   4.21       \<0.0001    0%        0          0.8454

  GXN + CG                2           49           4681           3.43            df = 2             2.81, 4.19   12.07      \<0.0001    21%       0.11       0.1177

  GXN + CG + additional   3           10           975            3.07            *P* = 0.7830       1.47, 6.41   2.99       0.00228     72%       0.98       \<0.0001
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------

CI is confidence interval; *Z* and *P* (eff) are statistical terms for evaluating overall effect; *I* ^2^, *χ* ^2^, and *P* (het) are statistical terms for assessing heterogeneity among studies.

###### 

Subgroups and sensitivity analysis on ECG outcomes.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------
                          Group       Number of\   Number of\     OR              Wilcoxon\           95% CI       *Z*        *P* (eff)   *I* ^2^   *χ* ^2^   *P* (het)
                                      RCTs         participants                   test                                                                        
  ----------------------- ----------- ------------ -------------- --------------- ------------------- ------------ ---------- ----------- --------- --------- -----------
  *M* score               ≤3          21           1995           2.47            *W* = 149           1.79, 3.41   5.53       \<0.0001    52%       0.28      0.0025

  \>3                     17          1709         2.71           *P* = 0.3945    2.17, 3.39          8.77         \<0.0001   0%          0         0.9136    

  Sample size             \<93        23           1734           2.42            *W* = 127           1.93, 3.02   7.72       \<0.0001    0%        0         0.9776

  ≥93                     15          1970         2.86           *P* = 0.1789    1.94, 4.21          5.33         \<0.0001   67%         0.37      0.0002    

  Number of authors       1           19           1872           2.30            *W* = 140           1.72, 3.08   5.65       \<0.0001    41%       0.16      0.0358

  \>1                     19          1832         2.98           *P* = 0.2428    2.34, 3.80          8.81         \<0.0001   13%         0.04      0.4435    

  Publication year        ≤2008       15           1268           2.49            *W* = 200           1.94, 3.20   7.17       \<0.0001    0%        0         0.9538

  \>2008                  23          2436         2.68           *P* = 0.4200    1.99, 3.61          6.47         \<0.0001   52%         0.26      0.0025    

  Trial date report       Reported    31           3069           2.43            *W* = 57            1.97, 3.00   8.29       \<0.0001    34%       0.12      0.0511

  Not reported            7           635          3.67           *P* = 0.0548    2.36, 5.70          5.79         \<0.0001   8%          0.03      0.5363    

  Baseline\               Reported    34           3318           2.64            *W* = 85            2.14, 3.24   9.20       \<0.0001    35%       0.12      0.0513
  comparison                                                                                                                                                  

  Not reported            4           386          2.29           *P* = 0.4325    1.25, 4.19          2.68         0.0074     23%         0.09      0.2200    

  Adverse\                Reported    19           1955           2.67            *W* = 192           2.16, 3.30   9.14       \<0.0001    0%        0         0.8792
  events                                                                                                                                                      

  Not reported            19          1749         2.54           *P* = 0.7480    1.80, 3.59          5.28         \<0.0001   54%         0.31      0.0020    

  Follow-up\              ≤14         27           2528           2.83            *W* = 129           2.34, 3.42   10.67      \<0.0001    2%        0         0.7120
  period (day)                                                                                                                                                

  \>14                    11          1176         2.21           *P* = 0.5407    1.37, 3.57          3.27         \<0.0001   65%         0.39      0.0024    

  GXN daily               6--200 mL   38           3704           2.59            *W* = 707.5         2.14, 3.15   9.68       \<0.0001    32%       0.11      0.0539

  dosage (mL)             6--30 mL    37           3648           2.58            *P* = 0.9662        2.12, 3.14   9.45       \<0.0001    33%       0.1175    0.0448

  GXN daily               \<20        4            352            1.89            *χ* ^2^ = 3.4288,   1.00, 3.55   1.96       0.0497      27%       0.1148    0.2425

  dosage (mL)             20          24           2324           2.80            df = 2              2.14, 3.66   7.51       \<0.0001    43%       0.1820    0.0246

  \>20                    10          1028         2.53           *P* = 0.1801    1.85, 3.46          5.81         \<0.0001   14%         0.0365    0.5413    

  Types of angina         Stable      4            374            3.03            *χ* ^2^ = 0.7010    1.80, 5.09   4.18       \<0.0001    0%        0         0.6688

  Unstable                16          1676         2.48           df = 2          1.95, 3.15          7.42         \<0.0001   10%         0.02      0.2332    

  Angina                  18          1654         2.60           *P* = 0.7043    1.87, 3.61          5.68         \<0.0001   46%         0.22      0.0191    

  Improvement             \>50%       38           3704           2.59            *W* = 1050          2.14, 3.15   9.68       \<0.0001    32%       0.11      0.0539

  \>80%                   38          3704         1.84           *P* \< 0.0001   1.59, 2.14          8.06         \<0.0001   0%          0         0.8367    

  GXN                     1           3            188            3.15            *χ* ^2^ = 1.6604    1.71, 5.81   3.68       0.0002      0%        0         0.9202

  GXN + CG                2           29           2963           2.68            df = 2              2.10, 3.41   7.98       \<0.0001    42%       0.17      0.0157

  GXN + CG + additional   3           6            553            2.09            *P* = 0.4360        1.45, 3.01   3.94       \<0.0001    0%        0         0.6382
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------

CI is confidence interval; *Z* and *P* (eff) are statistical terms for evaluating overall effect; *I* ^2^, *χ* ^2^, and *P* (het) are statistical terms for assessing heterogeneity among studies.

###### 

Metaregression analysis of the relationship between outcomes and the study characteristics.

  log OR                Number of RCTs   Number of participants   Factor      Coefficient   *z*      *P*
  --------------------- ---------------- ------------------------ ----------- ------------- -------- --------
  SYMPTOMS              65               6064                     *M* score   0.0663        0.4378   0.6615
  Sample size           −0.0013          −0.4955                  0.6203                             
  Number of authors     −0.0466          −0.6283                  0.5298                             
  Publication year      −0.0838          −1.9158                  0.0554                             
  Trial date report     −0.1931          −0.7634                  0.4453                             
  Baseline comparison   0.3299           1.3376                   0.1810                             
  Adverse events        −0.0965          −0.4646                  0.6422                             
  Follow-up period      0.0116           0.6126                   0.5401                             
                                                                                                     
  ECG                   38               3704                     *M* score   0.1191        0.7160   0.4740
  Sample size           0.0006           0.2938                   0.7689                             
  Number of authors     −0.0100          −0.1071                  0.9147                             
  Publication year      −0.0180          −0.4296                  0.6675                             
  Trial date report     −0.4255          −1.5606                  0.1186                             
  Baseline comparison   0.1520           0.4458                   0.6558                             
  Adverse events        0.1066           0.5300                   0.5961                             
  Follow-up period      −0.0423          −2.6000                  0.0093                             

###### 

Adverse events reported in the included studies.

                                Treatment group   Control group        
  ----------------------------- ----------------- --------------- ---- ----
  Headache                      10                4               9    3
  Dizziness                     1                 1               1    1
  Palpitation                   4                 2               7    3
  Skin ecchymosis               8                 2               6    1
  Serum transaminase elevated   1                 1               NR   NR
  Nausea                        1                 1               3    1
  Epigastria discomfort         4                 2               8    3
  Abnormal liver function       1                 1               NR   NR
  Skin allergy                  NR                NR              1    1
  General weakness              NR                NR              1    1
  Cold sweat                    NR                NR              5    1
  Hypotension                   NR                NR              1    1
  Skin mucosal bleeding         NR                NR              1    1
  No AEs                        0                 27              0    24
  Total AEs reports             30                9               43   11
  No AE report                  0                 28              0    29

NR: not reported; AEs: adverse events.

[^1]: Academic Editor: Myeong Soo Lee
